Máis información ― Galego

Acanthosis nigricans é unha manifestación cutánea dunha afección subxacente. Adoita aparecer nas dobras da pel, como o pescozo, as axilas e as inguas, con aspecto de manchas escuras, aveludadas, con bordos pouco claros. Esta condición adoita estar relacionada coa diabetes e coa resistencia á insulina; pero, en casos raros, pode indicar un cancro interno. Tamén pode aparecer debido a problemas hormonais ou ao tomar medicamentos específicos, como esteroides e pílulas anticonceptivas.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.

Acanthosis nigricans (AN) é unha afección común da pel relacionada con varios problemas de saúde, como a resistencia á insulina, a diabetes, a obesidade, certos tipos de cancro, os problemas hormonais e as reaccións aos medicamentos. O tratamento da AN céntrase en abordar as condicións subxacentes. Primeiro, os médicos buscan signos de síndrome de resistencia á insulina, que inclúe obesidade, colesterol alto, presión arterial elevada e diabetes tipo 2. Normalmente, prescriben retinoides tópicos como primeira opción terapéutica, pois poden mellorar o engrosamento da pel; con todo, poden non resolver completamente o escurecemento cutáneo. Outras opcións terapéuticas (salicylic acid, podophyllin, urea, calcipotriol) tamén requiren aplicación frecuente.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.